AI assistant
Cardlytics, Inc. — Director's Dealing 2020
Jan 18, 2020
33956_dirs_2020-01-17_09129dc6-6dd5-45c8-bec4-6ef8897e549d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cardlytics, Inc. (CDLX)
CIK: 0001666071
Period of Report: 2020-01-17
Reporting Person: SOMERS KIRK (Chief Legal & Privacy Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-17 | Common Stock | M | 778 | $20 | Acquired | 83671 | Direct |
| 2020-01-17 | Common Stock | S | 5409 | $83.06 | Disposed | 78262 | Direct |
| 2020-01-17 | Common Stock | S | 450 | $84.13 | Disposed | 77812 | Direct |
| 2020-01-17 | Common Stock | S | 919 | $84.88 | Disposed | 76893 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-01-17 | Employee Stock Option (Right to Buy) | $20.0 | M | 778 | Disposed | 2026-08-02 | Common Stock (778.0) | Direct |
Footnotes
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2019.
F2: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $82.83 to $83.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $83.86 to $84.21, inclusive.
F4: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $84.86 to $84.99, inclusive.
F5: This option became exercisable with respect to one quarter (1/4) of the shares of stock subject to this option on June 15, 2017 (the "Initial Vesting Date"). The option becomes exercisable in respect of the remaining shares in thirty-six (36) equal monthly installments commencing one (1) month after the Initial Vesting Date, provided the Reporting Person continuously provides service to the Issuer through each vesting period.